Novavax, Inc. (NVAX) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Novavax, Inc. (NVAX).

Download StockRank on Google Play Download StockRank on the App Store

Equity Overview

Price & Market Data

Price: $8.75

Daily Change: +$1.17 / 13.37%

Daily Range: $7.59 - $8.88

Market Cap: $1,422,096,512

Daily Volume: 17,691,723

Performance Metrics

1 Week: 32.03%

1 Month: 24.72%

3 Months: 47.56%

6 Months: 2.09%

1 Year: -22.85%

YTD: 9.20%

Company Details

Employees: 952

Sector: Health technology

Industry: Biotechnology

Country:

Details

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Selected stocks

AutoZone, Inc. (AZO)

MultiSensor AI Holdings, Inc. (MSAI)

Seagate Technology Holdings PLC (STX)